|
| Front page | | Contents | | Back | | Printing instructions |
Evaluation of Health Hazards by exposure to Triazines and Degradation Products
| Chemical |
Mammary gland tumours |
Attenuation of LH surge |
Disruption of the oestrous cycle |
Decreased serum testosterone level |
Decreased prostate, testes, seminal vesicles, and/or epididymal weights |
Delayed puberty |
Altered pregnancy outcome [1] |
| a) atrazine |
0.5/1.5 |
1.8/3.7 |
1.8/3.7 (rats)
<1/1 (pigs)
|
<50/50 |
25/50 |
<13/13 (male)
10/30
(female)
|
25/50 (rats)
5/75 (rabbits)
|
| b) simazine |
0.52/5.3 |
5/40 |
- [2] |
- |
- |
- |
- |
| c) terbutylazine |
7.8/53 |
- |
- |
|
5/20 (rabbits) |
- |
- |
| d) cyanazine |
0.26/1.4 |
- |
- |
- |
- |
- |
25/75 (rats)
1/2 (rabbits)
|
| e) desethyl atrazine (DEA) |
- |
- |
- |
No effect up to 174 |
11/22 |
11/22 (male)
- (female)
|
<44/44 |
| f) desisopropyl atrazine (DIA) |
- |
- |
- |
40/80 |
21/40 (rats)
3.8/19 (dogs)
|
10/21 (male)
- (female)
|
40/80 |
| g) desethyl terbutylazine |
- |
- |
- |
- |
- |
- |
- |
| h) desethyldesisopropyl atrazine (DACT) |
3.5/10 |
5/40 |
0.7/7.6 |
No effect up to 135 |
8.4/84 |
4.4/8.4 (male)
17/34
(female)
|
17/34 |
| i) hydroxyatrazine |
Not carcinogenic up to 22 |
- |
- |
- |
- |
<11/11 (male)
No delay
(female)
|
<91/91 |
| j) hydroxysimazine |
- |
- |
- |
- |
- |
- |
- |
| k) hydroxyterbutylazine |
- |
- |
- |
- |
- |
- |
- |
Footnotes
[1] Pre- and postimplantation loss, full litter resorption, delayed parturition
[2] - = No data or not able to determine a NOAEL/LOAEL from available data
| Front page | | Contents | | Back | | Printing instructions |
Version 1.0 October 2004, © Danish Environmental Protection Agency
|